share_log

CytomX Therapeutics Announces Initial Phase 1a Dose Escalation Data For Monotherapy CX-904; Demonstrated Favorable Safety Profile, Says 2 Of 6 Patients Confirmed Partial Response And All 6 Patients With Disease Control

Benzinga ·  May 8 16:50
CytomX Therapeutics Announces Initial Phase 1a Dose Escalation Data For Monotherapy CX-904; Demonstrated Favorable Safety Profile, Says 2 Of 6 Patients Confirmed Partial Response And All 6 Patients With Disease Control
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment